{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:12:59Z","timestamp":1790075579608,"version":"4.0.1"},"reference-count":5,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2014,8,4]],"date-time":"2014-08-04T00:00:00Z","timestamp":1407110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2014,10]]},"abstract":"Abstract<\/jats:title>The aim of the present review article was to summarize the efficacy and tolerability for mirabegron 50\u2009mg over 12 weeks and 1 year versus placebo (SCORPIO<\/jats:styled-content>) or tolterodine ER<\/jats:styled-content> 4\u2009mg (SCORPIO<\/jats:styled-content> and TAURUS<\/jats:styled-content>). After a 2\u2010week placebo run\u2010in, adults with overactive bladder symptoms for \u22653 months were randomized if, during a 3\u2010day micturition diary period before baseline, they had an average of \u22658 micturitions\/24\u2009h and \u22653 urgency episodes. Efficacy end\u2010points were change from baseline to each study visit and final visit in incontinence, micturitions, volume voided\/micturition, urgency incontinence, urgency (grades 3 or 4), level of urgency and nocturia. Additional secondary efficacy variables included patient\u2010reported outcomes. Safety variables included changes in treatment\u2010emergent adverse events and vital signs. For SCORPIO<\/jats:styled-content>, statistically significant improvements from baseline in efficacy variables and patient\u2010reported outcomes were seen with mirabegron versus placebo from week 4, and were maintained over time. For TAURUS<\/jats:styled-content>, numerical improvements in efficacy were evident from month 1, and were maintained throughout 12 months. Treatment\u2010emergent adverse events incidence was similar between groups, except for dry mouth, which was reported by fourfold (SCORPIO<\/jats:styled-content>) and threefold (TAURUS<\/jats:styled-content>) more patients taking tolterodine than mirabegron. Mirabegron 50\u2009mg for 12 weeks was associated with statistically significant improvements in objective measures of efficacy and patient\u2010reported outcomes. At final visit, improvements with mirabegron 50\u2009mg were statistically greater versus placebo. The efficacy profile of mirabegron 50\u2009mg appears to be maintained over 12 months.<\/jats:p>","DOI":"10.1111\/iju.12568","type":"journal-article","created":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:15:10Z","timestamp":1407197710000},"page":"960-967","source":"Crossref","is-referenced-by-count":40,"title":["Mirabegron 50\u2009mg once\u2010daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year"],"prefix":"10.1111","volume":"21","author":[{"given":"Christopher R","family":"Chapple","sequence":"first","affiliation":[{"name":"Department of Urology Royal Hallamshire Hospital Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Institute of Bladder and Prostate Health Weill Medical College of Cornell University New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mitcheson","sequence":"additional","affiliation":[{"name":"St Elizabeth's Medical Center Brighton Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Blauwet","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Huang","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd Chertsey Surrey UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd Chertsey Surrey UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vik","family":"Khullar","sequence":"additional","affiliation":[{"name":"Urogynaecology Department St Mary's Hospital Imperial College London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.115840"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.016"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.048"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.10.017"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.047"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.12568","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.12568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T19:02:15Z","timestamp":1696359735000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.12568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,4]]},"references-count":5,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1111\/iju.12568"],"URL":"https:\/\/doi.org\/10.1111\/iju.12568","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,4]]}}}